Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory Lymphoma
NCT07791615Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2026
- Primary completion
- Jun 2028
01
Overview
A Phase 2 trial of stapokibart in lymphoma, Natural killer T-cell lymphoma (NKTL), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
stapokibart
03
Conditions
lymphomaNatural killer T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on NCT07791615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07791615.